Valuation: IN8bio, Inc.

Market Cap 11.83M 10.38M 9.8M 8.93M 16.73M 1.13B 16.84M 117M 45.44M 579M 44.42M 43.46M 1.86B P/E 2026 *
-1.08x
P/E 2027 * -1.26x
Enterprise Value 11.83M 10.38M 9.8M 8.93M 16.73M 1.13B 16.84M 117M 45.44M 579M 44.42M 43.46M 1.86B EV / Sales 2026 *
-
EV / Sales 2027 * 10.7x
Free-Float
92.42%
Yield 2026 *
-
Yield 2027 * -
1 day+0.84%
1 week+11.11%
Current month+9.09%
1 month+2.56%
3 months-11.76%
6 months-25.47%
Current year-48.72%
1 week 1.06
Extreme 1.06
1.27
1 month 0.96
Extreme 0.96
1.27
Current year 0.88
Extreme 0.88
2.73
1 year 0.88
Extreme 0.88
2.73
3 years 0.88
Extreme 0.88
74.4
5 years 0.88
Extreme 0.88
282.72
10 years 0.88
Extreme 0.88
309.57
Manager TitleAgeSince
Chief Executive Officer 50 01/11/2015
Chief Tech/Sci/R&D Officer 72 01/11/2018
Director of Finance/CFO 43 08/02/2021
Director TitleAgeSince
Director/Board Member 50 01/11/2015
Director/Board Member 68 01/07/2019
Director/Board Member 64 04/08/2021
Date Insider Type Main position Quantity % Market Cap. Importance
27/05/26 Don

Director

-724,637 7.3589%
09/05/26 Free

Chairman

22,000 0.2234%
09/05/26 Free

Director

22,000 0.2234%
Change 5-day change 1-year change 3-year change Capi.($)
+0.84%+11.11%-42.58%-96.64% 11.73M
-3.30%+1.50%+51.24%+99.26% 71.94B
+1.25%-3.01%+40.12%+77.12% 59.35B
+2.12%+5.26%+32.50%+21.28% 27.16B
-3.06%-1.81%-13.10%+357.06% 26.54B
-0.75%+2.56%+0.45%-4.46% 24.93B
+0.40%+0.75%+22.91%-9.68% 20.61B
-1.70%-2.12%+146.86%+314.52% 15.03B
+0.36%-0.34%+50.32%+166.42% 14.36B
+0.21%+1.17%-8.07%+499.10% 14.2B
Average -0.36%+1.16%+28.07%+142.40% 27.41B
Weighted average by Cap. -0.78%-0.02%+36.12%+130.11%

Financials

2026 *2027 *
Net sales - 1.11M 971K 917K 836K 1.56M 106M 1.58M 10.97M 4.25M 54.17M 4.15M 4.06M 174M
Net income -20.96M -18.4M -17.37M -15.83M -29.64M -2.01B -29.85M -208M -80.53M -1.03B -78.71M -77.01M -3.3B -23.72M -20.82M -19.66M -17.92M -33.54M -2.27B -33.78M -235M -91.13M -1.16B -89.08M -87.15M -3.73B
Net Debt - -
Logo IN8bio, Inc.
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Employees
-
Date Price Change Volume
25/09/26 $1.200 +0.84% 67,589
24/09/26 $1.190 +8.18% 180,130
23/09/26 $1.100 -3.51% 22,606
22/09/26 $1.140 +7.55% 41,926
21/09/26 $1.060 -1.85% 13,775
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.200USD
Average target price
7.000USD
Spread / Average Target
+483.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INAB Stock